Equities Analysts Offer Predictions for RIGL FY2025 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Analysts at B. Riley lifted their FY2025 earnings per share estimates for Rigel Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the biotechnology company will post earnings of $0.93 per share for the year, up from their prior estimate of $0.84. B. Riley currently has a “Neutral” rating and a $24.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals’ FY2026 earnings at $1.10 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.49. The company had revenue of $53.33 million during the quarter, compared to analysts’ expectations of $43.87 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. During the same quarter in the prior year, the company posted ($0.50) EPS.

A number of other analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 5th. StockNews.com cut shares of Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 8th. Citigroup boosted their price target on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Finally, Cantor Fitzgerald raised their price objective on shares of Rigel Pharmaceuticals from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Rigel Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.40.

Rigel Pharmaceuticals Trading Down 0.5 %

NASDAQ RIGL opened at $18.81 on Thursday. Rigel Pharmaceuticals has a 1-year low of $7.48 and a 1-year high of $29.82. The company has a market capitalization of $336.08 million, a price-to-earnings ratio of 134.37 and a beta of 1.34. The stock’s 50 day moving average is $18.57 and its two-hundred day moving average is $19.79.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RIGL. Barclays PLC grew its stake in shares of Rigel Pharmaceuticals by 158.6% during the third quarter. Barclays PLC now owns 27,345 shares of the biotechnology company’s stock valued at $442,000 after purchasing an additional 16,772 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Rigel Pharmaceuticals by 45.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 26,238 shares of the biotechnology company’s stock valued at $425,000 after buying an additional 8,140 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Rigel Pharmaceuticals by 42.8% in the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 2,827 shares during the period. Los Angeles Capital Management LLC raised its position in shares of Rigel Pharmaceuticals by 15.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 86,001 shares of the biotechnology company’s stock worth $1,447,000 after acquiring an additional 11,499 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Rigel Pharmaceuticals during the fourth quarter valued at $588,000. Institutional investors and hedge funds own 66.23% of the company’s stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.